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and fishes approach: a critic
to double anti-thrombotics
or to double number of
ischaemic events?
We thank Dr Galli and colleagues for their
interest in our meta-analysis.1,2
We agree that a very short duration of triple
antithrombotic therapy (TAT) after percutan-
eous coronary intervention (PCI) may expose
patients with an indication to oral anticoagula-
tion (OAC) to higher ischaemic risk as previ-
ously reported and commented upon.3,4 The
proposed strategy of delaying dual therapy
(DAT) onset by some weeks (e.g. 1month) in
OAC patients undergoing PCI seems a reason-
able compromise and is being tested against a
still relatively short TAT duration of 3-month
DAPT in the @@@Management of High
Bleeding Risk Patients Post Bioresorbable
Polymer Coated Stent Implantation With an
Abbreviated vs. Standard DAPT Regimen
(MASTER-DAPT) Study.5
Our current meta-analysis integrates the
previous ones by clarifying the role of clinical
presentation (acute or chronic coronary syn-
drome, ACS or CCS) on safety and efficacy of
DAT vs. TAT1 and the novel message is that
the small, yet potentially clinically relevant, is-
chaemic risks associated with very short TAT
does not seem to be confined to ACS patients
only.
We respectfully disagree that our primary
analysis should have excluded ACS who did not
receive index PCI from the AUGUSTUS. As
clarified in a previous response letter,6 the ra-
tionale for including all study participants from
AUGUSTUS, firstly, comes from the need to
respect the randomization process while avoid-
ing arbitrary selection of a post-randomization
subgroups, which randomization was not strati-
fied for. We did exclude patients with ACS
without PCI in a sensitivity analysis, which con-
firmed the absence of interaction between clin-
ical presentation and ischaemic or bleeding
endpoints and which should not be misinter-
preted as suggested by the authors. Subgroup
analysis interpretation should be7,8 based on
the presence or absence of significant hetero-
geneity across strata (ACS and CCS) instead of
superiority statistics within each stratum (e.g.
PCI population or dabigatran doses).
Secondly, Galli et al. statement that ACS
without PCI comprises patients who cannot ex-
perience stent thrombosis (ST) is not accurate.
Galli et al. may want to value the fact that even
patients who did not receive PCI or stent im-
plantation at the time of the qualifying event
may still be exposed to the risk of ST because
of stenting procedures performed before the
qualifying visit. Indeed, 2 of the overall 32 defin-
ite/probable ST cases observed during the
study occurred in patients allocated to DAT
who received stent implantation prior to the
qualifying event and were therefore allocated in
the ACS no PCI stratum.6 We assume Galli et
al. do not fundamentally disagree with this ap-
proach considering that they also included all
AUGUSTUS patients in a prior meta-analysis
focusing on ST risks.9
The point raised on the ST definition is an
interesting one. We simply opted for the pri-
mary ST definition for each of the four included
trials, consisting of definite ST for three studies
and definite or probable ST for AUGUSUTUS.
The statement that the Academic Research
Consortium-2 recommends against the use of
definite or probable ST is not precise (the con-
sortium recommends against the use of pos-
sible ST due its low specificity). We again
assume Galli et al. would agree with this ap-
proach considering that they also included def-
inite or probable ST in the same prior meta-
analysis.9 It would have been desirable to use a
consistent ST definition across trials but the
rates of definite ST in patients with or without
ACS have not been published for the
AUGUSUTUS trial.
Galli et al. are also invited to read more care-
fully our manuscript regarding the apparent in-
consistency on ST risk in this compared to our
prior meta-analysis, as we wrote: ‘Due to miss-
ing information on ACS or SCAD presentation,
the present analysis excluded 41 (0.4%) among
the 10 234 originally included patients across
the four selected trials, which explains the ap-
parently inconsistent findings on ST in this com-
pared with a prior meta-analysis’.1
We pre-specified to pool both dabigatran
doses for the RE-DUAL PCI and run sensitivity
analyses for each of the employed dabigatran
regimens.3 This approach respects the RE-
DUAL trial design and has been used also by
other authors,10 including Galli et al.9 The tactic
of using both doses separately in the same
pooled analysis is highly questionable due to
the duplication of the control group population,
which is a mere artefact. RE-DUAL PCI
included 981 patients in the TAT group and
acuity of clinical presentation was known for
980 (475 ACS and 505 CCS) in whom a total of
29 myocardial infarction (MI) events occurred
(16 in ACS and 13 in CCS) and were included
in the present analysis. With the authors‘ ap-
proach, which follows the ‘multiplication of
loaves and fishes’ principle, the TAT group now
comprises as many as 1743 patients (844 ACS
and 899 CCS) in whom a total of 51 MI events
has apparently occurred (27 in ACS and 24 in
CCS), which is obviously a pure fabrication and
does not correspond to reality. We assume
Galli et al. would agree with this approach con-
sidering that they also recently applied the
same.9
Finally, testing each dabigatran dose separ-
ately against the TAT group further introduces
serious biases in the analysis due to different pa-
tient eligibility towards the two tested dabiga-
tran regimens across participating regions. In
RE-DUAL PCI, all patients in the USA and non-
elderly patients in other countries were ran-
domly assigned to the 110-mg DAT, the 150-
mg DAT, or TAT in a 1:1:1 ratio. Elderly
patients outside the USA were randomly
assigned to the 110-mg DAT or TAT in a 1:1
ratio; they were not eligible to be assigned to
the 150-mg DAT, in accordance with the rec-
ommendations of the dabigatran label in those
countries.
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